Adial Pharmaceuticals (ADIL) announced the filing of an update to the provisional patent application for AD04 which was filed in July 2024, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients. The patent, once granted, is expected to protect Adial’s core assets out to at least 2045.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals secures U.S.-based manufacturing through agreements
- Adial Pharmaceuticals Completes $3.6M Public Offering
- Adial Pharmaceuticals prices 11.1M shares at 32.51c in public offering
- Adial Pharmaceuticals Reschedules 2025 Annual Meeting Date
- Adial Pharmaceuticals submits briefing package to guide upcoming FDA meeting